Bryan Franklin Curtin1,2, Lauren Ann Gamble3, Samuel Ali Schueler1, Samantha Marilyn Ruff3, Martha Quezado4, Markku Miettinen4, Grace-Ann Fasaye5, Monica Passi1, Jonathan Matthew Hernandez3, Theo Heller1, Christopher Koh1, Jeremy Lee Davis6. 1. Digestive Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. 2. Division of Gastroenterology and Motility, Mercy Medical Center, Baltimore, MD, USA. 3. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. 4. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 5. Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. 6. Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD, 20892, USA. jeremy.davis@nih.gov.
Abstract
BACKGROUND: Germline inactivating variants in the CDH1 tumor suppressor gene impart an elevated lifetime risk of diffuse gastric cancer. The current endoscopic surveillance method depends upon random gastric biopsies for early cancer detection. METHODS: Asymptomatic adults with pathogenic or likely pathogenic CDH1 variants referred for endoscopic gastric cancer surveillance were included in this retrospective cohort. Upper gastrointestinal endoscopy was performed according to the consensus Cambridge method, in the early period, or a systematic (Bethesda) protocol as part of an ongoing natural history study. The primary outcome measure was cancer detection. RESULTS: Collectively, 135 endoscopic surveillance procedures were performed in 120 patients. Twenty-six (19%, 26/135) procedures were performed using Cambridge method and 109 (81%) using the Bethesda protocol. Gastric signet ring cell carcinomas were detected in 15% (4/26) using the Cambridge method and 36% (40/109) using the Bethesda protocol (p < 0.05). Almost half (44.2%, 53/120) of patients later elected for prophylactic total gastrectomy, of whom 51 (96%, 51/53) had a signet ring cell carcinoma (T1a) discovered by histopathology. On a per endoscopy basis, the false-negative rates of detection using Cambridge method and Bethesda protocol were 80% (12/15) and 37.7% (17/45), respectively (p < 0.01). CONCLUSIONS: Gastric cancer detection was more frequent with implementation of a systematic surveillance protocol in CDH1 variant carriers. Given the decision for prophylactic surgery is often made by patients in the context of family history and pathologic result of surveillance biopsies, we propose the Bethesda protocol offers patients an opportunity to make more informed decisions.
BACKGROUND: Germline inactivating variants in the CDH1 tumor suppressor gene impart an elevated lifetime risk of diffuse gastric cancer. The current endoscopic surveillance method depends upon random gastric biopsies for early cancer detection. METHODS: Asymptomatic adults with pathogenic or likely pathogenic CDH1 variants referred for endoscopic gastric cancer surveillance were included in this retrospective cohort. Upper gastrointestinal endoscopy was performed according to the consensus Cambridge method, in the early period, or a systematic (Bethesda) protocol as part of an ongoing natural history study. The primary outcome measure was cancer detection. RESULTS: Collectively, 135 endoscopic surveillance procedures were performed in 120 patients. Twenty-six (19%, 26/135) procedures were performed using Cambridge method and 109 (81%) using the Bethesda protocol. Gastric signet ring cell carcinomas were detected in 15% (4/26) using the Cambridge method and 36% (40/109) using the Bethesda protocol (p < 0.05). Almost half (44.2%, 53/120) of patients later elected for prophylactic total gastrectomy, of whom 51 (96%, 51/53) had a signet ring cell carcinoma (T1a) discovered by histopathology. On a per endoscopy basis, the false-negative rates of detection using Cambridge method and Bethesda protocol were 80% (12/15) and 37.7% (17/45), respectively (p < 0.01). CONCLUSIONS: Gastric cancer detection was more frequent with implementation of a systematic surveillance protocol in CDH1 variant carriers. Given the decision for prophylactic surgery is often made by patients in the context of family history and pathologic result of surveillance biopsies, we propose the Bethesda protocol offers patients an opportunity to make more informed decisions.
Entities:
Keywords:
Cancer early detection; Endoscopy; Gastric cancer; Hereditary cancer syndromes
Authors: Samantha Hansford; Pardeep Kaurah; Hector Li-Chang; Michelle Woo; Janine Senz; Hugo Pinheiro; Kasmintan A Schrader; David F Schaeffer; Karey Shumansky; George Zogopoulos; Teresa Almeida Santos; Isabel Claro; Joana Carvalho; Cydney Nielsen; Sarah Padilla; Amy Lum; Aline Talhouk; Katie Baker-Lange; Sue Richardson; Ivy Lewis; Noralane M Lindor; Erin Pennell; Andree MacMillan; Bridget Fernandez; Gisella Keller; Henry Lynch; Sohrab P Shah; Parry Guilford; Steven Gallinger; Giovanni Corso; Franco Roviello; Carlos Caldas; Carla Oliveira; Paul D P Pharoah; David G Huntsman Journal: JAMA Oncol Date: 2015-04 Impact factor: 31.777
Authors: Rosa M Xicola; Shuwei Li; Nicolette Rodriguez; Patrick Reinecke; Rachid Karam; Virginia Speare; Mary Helen Black; Holly LaDuca; Xavier Llor Journal: J Med Genet Date: 2019-07-11 Impact factor: 6.318
Authors: Yijun Chen; Kerry Kingham; James M Ford; James Rosing; Jacques Van Dam; R Brooke Jeffrey; Teri A Longacre; Nicki Chun; Allison Kurian; Jeffrey A Norton Journal: Ann Surg Oncol Date: 2011-03-18 Impact factor: 5.344
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Maegan E Roberts; John Michael O Ranola; Megan L Marshall; Lisa R Susswein; Sara Graceffo; Kelsey Bohnert; Ginger Tsai; Rachel T Klein; Kathleen S Hruska; Brian H Shirts Journal: JAMA Oncol Date: 2019-09-01 Impact factor: 31.777
Authors: Emma Z Mi; Ella Z Mi; Massimiliano di Pietro; Maria O'Donovan; Richard H Hardwick; Susan Richardson; Hisham Ziauddeen; Paul C Fletcher; Carlos Caldas; Marc Tischkowitz; Krish Ragunath; Rebecca C Fitzgerald Journal: Gastrointest Endosc Date: 2017-07-06 Impact factor: 9.427
Authors: Yean Cheant Lim; Massimiliano di Pietro; Maria O'Donovan; Susan Richardson; Irene Debiram; Susan Dwerryhouse; Richard H Hardwick; Marc Tischkowitz; Carlos Caldas; Krish Ragunath; Rebecca C Fitzgerald Journal: Gastrointest Endosc Date: 2014-01-25 Impact factor: 9.427